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Abstract
Although the factors involved in cirrhotic ascites have been studied for a century, a number of observations are
not understood, including the action of diuretics in the treatment of ascites and the ability of the plasma-ascitic
albumin gradient to diagnose portal hypertension. This communication presents an explanation of ascites based
solely on pathophysiological alterations within the peritoneal cavity. A quantitative model is described based on
experimental vascular and intraperitoneal pressures, lymph flow, and peritoneal space compliance. The model’s
predictions accurately mimic clinical observations in ascites, including the magnitude and time course of changes
observed following paracentesis or diuretic therapy.
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Background
Ascites commonly is regarded as a clinical condition
that can be understood in terms of classic physiological
principals. The fundamental factors involved in the for-
mation of ascites were established over a century ago
when Starling [1] used observations of thoracic duct
lymph flow and fluid absorption from the peritoneal
space to support his classic description of the forces
that determine capillary fluid balance.
Over the past 30 years, ascites research largely has
focused on associated systemic abnormalities such as
increases in cardiac output, blood volume, renal sodium
retention and reduction in total systemic vascular resis-
tance. Whether these systemic abnormalities are the
effect or cause of ascites has been controversial. Rocco
and Ware [2] review the two older competing hypoth-
eses: 1) the “underfill” theory in which ascites formation
is the primary event causing the systemic changes, ver-
sus 2) the “overflow” theory in which renal sodium
retention is the primary event. Recent reports [3-9],
which have emphasized the renal and systemic effects of
vasoactive compounds such as nitric oxide and the
“hyperdynamic syndrome”,f a v o rt h e“forward” theory,
which represents a synthesis of the underfill and over-
flow theories.
This focus on renal and systemic effects has led inves-
tigators to lose sight of the local factors within the peri-
toneal cavity that actually are responsible for the
accumulations of ascites. For example, a recent review
[10] of ascites summarized the pathogenesis as follows:
“The most acceptable theory for ascites formation is
peripheral arterial vasodilation leading to underfilling of
circulatory volume. This triggers the baroreceptor-
mediated activation of renin-angiotensin-aldosterone sys-
tem, sympathetic nervous system and nonosmotic release
of vasopressin to restore circulatory integrity. The result
is an avid sodium and water retention, identified as a pre-
ascitic state. This condition will evolve in overt fluid
retention and ascites, as the liver disease progresses.
Once ascites is present, most therapeutic modalities are
directed on maintaining negative sodium balance, includ-
ing salt restriction, bed rest and diuretics.”
How the above described systemic changes translate
into ascites accumulation is poorly understood at the
quantitative level, and, in fact, is seldom discussed (as
illustrated by the above quote). As a result, several clini-
cally important observations remain unexplained. For
example, how do the systemic alterations induced by
salt restriction and diuretics lead to a reduction in
ascites [11] and why does the commonly employed mea-
surement of plasma-ascitic fluid albumin gradient
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to better understand the physiology of ascites, we pre-
sent what appears to be the first quantitative model of
the formation and removal of ascitic fluid. In this
model, ascites accumulation is explained solely by
pathophysiological alterations within the peritoneal cav-
ity; systemic abnormalities are considered relevant only
to the extent that they alter intraperitoneal physiology.
Insights derived from this model may provide answers
to previously unexplained clinical observations in
patients with ascites.
Section I of the Discussion provides a brief quantitative
description of the factors involved in fluid balance in the
peritoneal space of normal subjects. Section II presents an
analysis of the pathological abnormalities in the peritoneal
cavity that are involved in the accumulation of ascites. This
discussion includes mechanistic explanations for several
clinically important, but poorly understood phenomena.
Finally, in Section III, using a reasonable set of assump-
tions, a quantitative physical model describing ascites accu-
mulation is developed and discussed. This model
accurately predicts the magnitude and time course of the
changes in ascites volume that are observed clinically with
diuretic treatment or paracentesis. In sections I-III we have
focused on the key factors and main supporting experi-
mental results. The attached Additional file 1 (Section A),
provides a more detailed discussion of the evidence sup-
porting (or contradicting) the model’s assumptions.
Discussion
I. Physiological model of normal peritoneal fluid balance
A schematic diagram of the peritoneal space is shown in
Figure 1. Two compartments exchange with this space,
the liver and the “intestine”.T h e“intestine” is assumed
to represent all non-hepatic, intraperitoneal organs
(including the mesentery). The liver has a dual blood
flow–the portal vein and the hepatic artery. One branch
of the hepatic artery (about 2/3 of flow) directly con-
nects to the sinusoids and the other branch supplies the
peribiliary capillaries of the bile ducts which then drain
into the sinusoids [12]. The intestinal capillary and liver
sinusoidal colloid osmotic pressures are assumed to
equal the systemic plasma colloid osmotic pressure (ΠP).
A. Fluid transport across the intestinal capillaries
Fluid balance across the intestinal capillaries is a function
of the hydrostatic and colloid osmotic pressures. Since the
intestinal capillary membrane is relatively impermeable to
protein, the volume flux between the capillary and tissue
space (JC) is described by Starling’sr e l a t i o n :
JC = LC[(PC − PI) − (ΠP − ΠI)] (1)
where JC is the flux across the capillary, LC is the capil-
lary hydraulic permeability, and PC and PI are the
hydraulic pressures in the capillary and tissue and ΠP and
ΠI are the oncotic pressures in the capillary and tissue.
The capillary membrane has a slow diffusional leak of pro-
tein (primarily albumin). In the normal steady state, this
slow leak is balanced by protein removal from the tissue
space by the “intestinal” lymph flow, and the interstitial
protein concentration is roughly 70% of the plasma con-
centration [13]. Because the hydraulic permeability is large
compared to this slow leak, to a first approximation JC ≈ 0
and the difference in hydraulic pressure across the capil-
lary equals the oncotic pressure difference:
 P −  I = PC − PI (2)
As discussed in the next section, PI is approximately
equal to PA (intra-abdominal pressure) so that:
ΠI ≈ ΠP + PA − PC (3)
Normally, the plasma colloid osmotic pressure (ΠP)i s
about 25 mm Hg and the supine intra-abdominal pres-
sure (PA)i sa b o u t2m mH g[ 1 4 ] .A l t h o u g hd i r e c t
experimental measurement of the intestinal hydrostatic
capillary (PC) and tissue colloid osmotic (ΠI)p r e s s u r e s
are difficult and uncertain (see Additional file 1 Section
IA for more details), an estimate of the normal values
[15] are PC =9a n dΠI = 18 mm Hg, which are consis-
tent with eq. (3). This is a dynamic equilibrium. If, for
example, capillary pressure (PC) is raised (e.g., by con-
stricting the portal vein), there will be an initial increase
in capillary filtration (JC, eq. (1)) increasing intestinal
lymph flow and “washing down” t h et i s s u ep r o t e i n( ΠI)
until a new steady state relation (eq. (3)) is established.
B. Fluid transport across the intestinal mesothelium
The mesothelial membrane (Figure 1) separates the
intestinal tissue space from the peritoneal space. It is
a s s u m e dt h a tt h e“intestinal” mesothelial and capillary
membrane have similar protein permeability properties,
with the rate of fluid exchange between the tissue and
peritoneal space (JI) described by:
JI = LI[(PI − PA) − (ΠI − ΠA)] (4)
where PA and ΠA are the hydrostatic and colloid
osmotic pressures in the peritoneal (ascitic) space and LI
is the mesothelial hydraulic permeability. It is also
assumed that the mesothelial membrane cannot support
appreciable mechanical forces so that, to a first approxi-
mation, there is no hydrostatic pressure gradient across
this membrane:
PI = PA (5)
and eq. (4) reduces to:
JI = LI[ΠA − ΠI] (6)
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IB, the mesothelial barrier is ignored in the peritoneal
dialysis literatures where it is assumed that this mem-
brane is highly permeable to both protein and fluid.
This assumption would not significantly change any of
our model results or conclusions and, as is shown Sec-
tion III, the quantitative steady state relations are identi-
cal, with or without, a mesothelial barrier. We feel
experimental evidence supporting a significant mesothe-
lial barrier is sufficient to keep this barrier in the model.
C. Fluid transport across the liver
The fenestrated liver sinusoids allow relatively free pas-
sage of proteins between the blood and tissue [16].
Thus, to a first approximation, the sinusoidal and tissue
hydrostatic [17] and colloid osmotic pressures [18] are
approximately equal:
PL ≈ PS ΠL ≈ ΠP (7)
The normal liver sinusoidal pressure (PS)a n d ,t h e r e -
fore, the liver tissue pressure (PL)i sa b o u t5m mH g
(see Section IIC), significantly greater than the normal
pressure in the peritoneal space (PA ≈ 2 mmHg). It fol-
lows that the liver capsule, in contrast to the intestinal
mesothelium, is able to maintain a hydrostatic pressure
difference between the tissue and peritoneal space.
Assuming that the capsule is relatively impermeable to
albumin, the pressure difference between the liver tissue
and peritoneal space (PL-PA) would have to overcome
t h et i s s u ec o l l o i do s m o t i cp r e s s u r e( ≈ 25 mmHg) before
there would be net fluid movement across the liver sur-
face. As is discussed below, fluid leaks from the liver
into the peritoneal space at pressures well below 25 mm
Hg indicating that the source of this fluid is rupture of
either the capsule or surface lymphatics.
D. Fluid exchange in the peritoneal space
Normal fluid movement between the peritoneal space
and the systemic circulation is a combination of the
“intestinal” mesothelium (JI) flux and the peritoneal
lymph drainage (as discussed above, liver fluid flux is
normally low). Since the mesothelial hydraulic perme-
ability (LI) should be relatively large compared to the
normal small lymph flow, to a first approximation JI =0
and, from eq. (6), the peritoneal (ΠA)a n dt h e“intest-
inal” (ΠI) colloid osmotic pressures are equal:
ΠA ≈ ΠI (8)
The peritoneal lymph drainage (Figure 1) removes
fluid in bulk, with no sieving of the peritoneal protein
concentration [19,20]. Our limited understanding of the
rate of peritoneal lymph flow and its dependence on
intra-abdominal pressure and volume is discussed in
more detail in Section IID.
II. Factors involved in the formation of Ascites in portal
hypertension
A. Increase in portal vein pressure
In the absence of increased hepatic sinusoidal pressure,
marked elevations in portal vein pressure are required
to induce ascites. Moderate increases in portal pressure
induced experimentally via portal vein constriction [21]
or clinically by portal vein thrombosis [22] do not result
in appreciable ascites. This observation is explained by
the above model. The peritoneal cavity normally con-
tains a small amount of fluid (up to 100 ml) that is in
osmotic equilibrium with intestinal tissue (eq. (8)). A
rise in portal pressure elevates intestinal capillary pres-
sure, increasing capillary filtration (JC, eq. (1)) and
intestinal lymph flow. This washes out tissue protein,
and the tissue colloid osmotic pressure (ΠI)f a l l su n t i la
new steady state (eq. (2)) is established. This decrease in
ΠI produces an osmotic water flux from intestinal tissue
into the peritoneal space (eq. (6)), diluting the peritoneal
protein until a new steady state is reached in which
peritoneal colloid osmotic pressure equals the low value
in the intestinal tissue (eq. (8)). This initial increase in
peritoneal (ascitic) volume is small. For example, a
reduction of tissue protein by a factor of two would
result in a doubling of the initial small peritoneal
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Figure 1 Schematic diagram of the peritoneal space.T h e
“intestine” represents all non-hepatic, intraperitoneal organs
(including the mesentery). The symbols P and Π indicate the
hydrostatic and colloid osmotic pressure of the different
compartments. See “Notation” for a definition of all the terms.
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brings the peritoneal volume back towards its original
volume. The important point is that a new equilibrium
will be rapidly established in which the volume flux
between the intestine and peritoneal space is zero at the
increased portal and intestinal capillary pressure, and
the elevation in portal pressure does not produce appre-
ciable ascites. This dynamic equilibrium reaches its limit
when the intestinal tissue albumin (ΠI, eq. (3)), is
washed down to 0, corresponding to a maximum limit-
ing capillary pressure (PC
max) described by:
Pmax
C =  P + PA (9)
At the normal PA of 2 mmHg, this limiting capillary
pressure is about 27 mm Hg. Since the intestinal capil-
lary pressure is about 3 mm Hg greater than portal vein
(PPV) pressure [15,23], this limit corresponds to a PPV of
about 24 mm Hg. This is consistent with the experi-
mental results of Witte et. al. [24] that the intestine did
not leak large volumes of ascetic fluid until the portal
pressure reached about 26 mm Hg (PA = 2 mmHg).
Since PC
max depends on PA (eq. (9)), a patient with
severe ascites and a PA of 15 mm Hg would not exceed
this maximum until PPV was greater than 37 mm Hg, a
value seldom observed clinically. (See Additional file 1,
Section IE for more details).
B. Increase in liver sinusoidal pressure
Ascites readily forms when liver sinusoidal pressure is
increased secondary to cirrhosis or obstruction of the
hepatic veins or the inferior vena cava. This can be
explained in terms of the model shown in Figure 1. As
discussed above, the sinusoids are highly permeable to
albumin and the liver tissue hydrostatic and colloid
osmotic pressures are approximately equal to that of the
sinusoids (eq. (7)), producing a hydrostatic pressure dif-
ference of (PL -P A) across the liver capsule. Increase in
the sinusoidal pressure results in a flux of fluid into the
interstitial space which elevates tissue pressure and
hepatic lymph flow [17,18]. The crucial event in ascites
is the rupturing of either the liver capsule and/or the
surface lymphatics allowing high protein tissue fluid (ΠL
≈ ΠP, eq. (7)) to leak into the peritoneal space.
This protein leak from the liver surface is supported
by a number of direct observations. Experimental infer-
ior vena cava constriction leads to obvious “weeping” of
fluid droplets from the liver surface [25-27] while the
other visceral surfaces appear dry [27]. Clinical evidence
that the weeping liver is the source of ascites protein is
provided by the observation of Dumont and Mulholland
[28] that “Lymph leaking from clusters of bulging lym-
phatics on the liver capsule and at the porta hepatis
often is encountered at laparotomy in patients with
Laennec’s cirrhosis”. Kuntz and Kuntz [29] provide a
dramatic image of “Numerous, partially ruptured lym-
phocysts ... on the liver surface with extravasation of
protein-rich lymph in alcoholic cirrhosis” (Figure 16.5,
p. 298). Tameda et. al. [30] observed “small lymphatic
vesicles” on the liver surface in 65 out 372 cirrhotic sub-
jects during peritoneoscopy. During laparoscopy, Heit et.
al. [31] reported that 4 of 10 cirrhotic livers had surface
“...lymphatic blebs indicating dilated lymphatic channels
... and all 4 of these cases were complicated by ascites.”
Blebs were not seen in the absences of ascites. (see
Additional file 1, Section ID for more details).
The protein concentration in ascitic peritoneal fluid in
portal hypertension is low, roughly equal to the protein
concentration of intestinal lymph [13]. There is a defi-
nite “capillarization” of liver sinusoids in cirrhosis
[32,33] and some authors [34,35] have suggested that
the ascites protein is roughly equal to the low liver tis-
sue protein produced by this capillarization. However,
even in severe cirrhosis sinusoidal fenestra are still pre-
sent [33] and the liver lymph protein/plasma ratio
(which is a measure of tissue protein) is about 0.6,
much greater than the corresponding ascites protein
ratio of 0.17 [13]. Furthermore, this liver lymph protein/
plasma ratio of 0.6 may underestimate the liver tissue
protein because of lymphatic contributions from peri-
biliary capillaries and admixture from intestinal lymph
[33]. An alternative explanation for this low ascites pro-
tein, which is directly supported by our quantitative
model (Section III), is that the high protein fluid leaking
from the liver pulls fluid osmotically from the “intest-
inal” tissue space (eq. (4)), diluting the peritoneal fluid
protein until it roughly equals the intestinal tissue pro-
tein concentration. This implies that the rate of forma-
tion of ascitic fluid is determined primarily by two
factors: the rate of protein leak from the liver and the
interstitial protein concentration of the intestine, a con-
cept alluded to in the older literature [36,37] but seldom
discussed in recent reviews of ascites. This mechanism
provides a straight forward explanation for use of the
serum-ascites albumin gradient (SAAG) in the differen-
tial diagnosis of ascites (see Section IIE).
Since the ascites protein concentration in portal
hypertension is only about 1/3 of that of the fluid leak-
ing from the liver, the bulk of ascitic fluid is derived
from the intestine rather than the liver. This fluid move-
ment from the intestine into the peritoneum continues
as long as the liver continues to leak protein. Homeosta-
sis is achieved when the rising ascitic pressure (PA)
increases the rate of peritoneal lymph and protein drai-
nage until it equals the rate at which protein leaks from
the liver. Although it has been hypothesized that
increased ascites pressure (PA)s h o u l ds l o wt h er a t eo f
liver leak [17], as is discussed below, this should be a
small to negligible effect because an increase in PA
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cial parameter characterizing the rate of leakage of fluid
from the liver is the value of (PL -P A). Experimental
measurements of this parameter are discussed in the
next section.
C. Interpretation of experimental hepatic “wedge” and
“free” pressure and assessment of the pressure difference
across the liver capsule (PL -P A)
Since sinusoids are leaky to protein, the liver hydrostatic
tissue pressure (PL) is nearly equal to the “average” sinu-
soidal pressure (PS, eq. (7)). The site of the liver flow
resistance is controversial, with evidence for both pre-
sinusoidal [38] and post-sinusoidal [39] sites. Recent
results suggest that the resistance is primarily in the
sinusoids and is distributed relatively uniformly along
the sinusoidal length both in normal and cirrhotic con-
ditions [40-42]. Using this latter assumption:
PS ≈ (PHV + PPV)/2 ≈ PL (10)
Since direct access to the portal vein requires a lapar-
otomy, virtually all measurements have been obtained
indirectly via hepatic vein catheterization. When flow is
obstructed via “wedging” of a catheter in a hepatic vein,
the measured pressure should equal the portal pressure
(assuming no anastomoses between the vessels of the
wedged liver segment and vessels with low pressure).
Such is the case in cirrhosis, where “wedged” pressure
measurements have been shown to equal portal vein
pressures [43-46]. The pressure when the catheter is
withdrawn to an unwedged ("free”) position in a hepatic
vein provides a measure of the hepatic vein (or inferior
venal cava) pressure [47,48].
PWedge ≈ PPV PFree ≈ PHV (11)
It is useful to briefly summarize the relations between
all the pressures in the portal system (see Figure 1) for
the normal condition:
NormalRelations : PA < PRA +2
PHV = PRA +2 PPV = PRA + FLRL +2 PC = PRA + FLRL + 5
PS ≈ (PHV + PPV)/2 PL ≈ PS PI ≈ PA
(12)
where FL and RL are the liver flow and resistance and
where the hepatic vein pressure (PHV)i sa s s u m e dt ob e
about 2 mm greater than the right atrial pressure (PRA)
([49] and see Table 1) and the intestinal capillary pres-
sure (PC) is about 3 mm greater than the portal vein
pressure (PPV)[ 1 5 , 5 0 ] .A st h e s er e l a t i o n ss h o w ,a l lt h e
pressures in the portal system can be directly related to
systemic right atrial pressure and the liver flow and
resistance.
There is a dramatic change in these relations if there
is gross ascites and the ascites pressure (PA)b e c o m e s
greater than the normal hepatic vein pressure. Since the
hepatic veins (and inferior vena cava) are collapsible, the
hepatic vein pressure must be minimally greater than
the intra-abdominal pressure, so that PA ≈ PHV ≈ PFree.
Hernriksen et. al. [47] have directly confirmed this rela-
tion and shown that PFree ≈ PA o v e raw i d er a n g eo f
p r e s s u r e si np a t i e n t sw i t ha scites. This condition pro-
duces a different set of relations:
Ascites : PA >= PRA +2
PHV = PA PPV = PA + FLRL PC = PA + FLRL +3
PS ≈ (PHV + PPV)/2 PL ≈ PS PI ≈ PA
(13)
As can be seen, for this condition the portal pressures
become linearly dependent on PA and are uncoupled
from the systemic right atrial pressure. This shift
between these two pressure domains, which commonly
is ignored, has important implications for interpreting
portal pressure measurements (see below). At high peri-
toneal pressure, all the liver and intestinal pressures
become additively dependent on PA and changes in PA
have no effect on the relative pressure relations. This
has already been referred to above (Section IIB) when it
was concluded that increases in ascitic pressure do not
change the value of (PL -P A) and therefore do not slow
the leak of liver protein. This constancy of (PL -P A)a s
PA increases is based on the assumption that the liver
flow (FL) and resistance (RL) are constant (eq. (13)). In
fact, one might expect a small decrease in FL as
increases in PA and PPV leads to increased portal to sys-
temic shunting. This decrease in FL should slightly
decrease the value of (PL -P A). This prediction is
directly supported by the measurements of Luca et. al.
[79] of the free and wedge pressure before and after
paracentesis. The wedge pressure fell by 7.4 mm Hg
(31.9-24.5) and there was a nearly equivalent 5.9 mm
H gf a l li nt h ef r e ep r e s s u r ew i t hP L -P A (eq. (15))
decreasing by only 0.85 mm Hg.
The difference between the wedge and free pressure,
the “hepatic vein pressure gradient” (PHVPG =P Wedge -
PFree ≈ PPV -P HV =F LRL), is directly proportional to the
resistance of the liver to portal flow. Thus, this gradient
commonly is employed to characterize the severity of
portal hypertension in cirrhotic subjects. PHVPG is also
used clinically as a surrogate measure of the driving
pressure for the formation of ascites. This can be mis-
leading because it ignores the importance of the two
pressure domains (eqs. (12) and (13)) discussed above.
The critical parameter characterizing the rate of ascites
formation is the pressure difference across the liver cap-
sule (PL -P A). With low intraperitoneal pressure, this
pressure difference (calculated using eq. (12)) equals:
PL − PA =( PPV + PHV)/2 − PA
≈ (PWedge + PFree)/2 − PA
(14)
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Drug Δt CO HBF PRA Wedge Free PHVPG Resistance Δ(PL -P A) Comments
Hours Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Eq.
16
Eq.
17
Spironolactone
[51] 1440 8.6 7.3 1.33 1.24 3.5 1.8 23.9 20.8 6.4 5.5 17.6 15.3 13.2 12.3 2.0 1.15 No ascites
[52] 168 6.75 NR NR NR 26.3 23.5 9.8 10.6 16.5 12.9 NR NR 1.0 1.8 70% ascites
[53] 672 6.48 5.76 1.00 1.00 NR 18.7 15.7 2.2 2.8 16.5 12.9 16.5 12.9 1.2 1.8 No ascites
[54] 1344 5.5 4.9 1.0 0.94 NR 22.4 20.1 4.9 4.4 17.5 15.7 17.5 16.7 1.4 0.9 No ascites,
unrestricted Na
+
Furosemide
[53] 672 8.4 6.78 1.29 1.08 NR 17.6 16.7 3.9 3.1 13.7 13.6 10.6 12.5 0.85 0.05 No ascites
[55] 1 6.6 5.5 1.49 0.82 5 3 31.1 27.7 9.0 8.2 22.1 19.5 14.8 23.8 2.1 1.3 Acute affect, 60%
ascites
Propranolol
[56] 1 7.6 5.9 1.06 0.862 3.7 5.5 23.8 22.9 5.7 7.0 18.1 15.9 17.1 18.4 -0.2 1.1 Varices and/or
ascites
[57] 240 8.13 5.36 1.5 1.8 NR 29.7 26.9 8.6 10.1 21.1 16.8 14.1 9.3 0.65 2.15 45% ascites
[58] 672 6.05 5.0 0.93 0.826 1.9 1.1 19.3 14.5 3.6 3.2 15.1 11.4 16.2 13.8 2.6 1.85 No ascites
[59] 1/4 6.33 5.01 NR NR 27.9 25.7 7.0 8.0 20.9 17.7 NR NR 0.6 1.6 Mild–6% ascites
[59] 1/4 7.17 5.76 NR NR 31.3 29.2 7.1 8.4 24.2 20.8 NR NR 0.4 1.7 Moderate–72%
ascites
[59] 1/4 9.03 5.92 NR NR 32.1 29.6 8.8 9.5 23.4 20.1 NR NR 0.9 1.65 Severe–100%
ascites
[60] 1848 7.6 5.8 1.25 1.01 5.8 6.4 28.8 25.9 8.5 8.3 20.3 17.6 16.2 17.4 1.55 1.35 Varices, PHVPG>1 2
[61] 2160 NR NR NR 27.5 26.0 10.0 13.9 17.3 12.1 NR NR -1.2 2.6 100% variceal bleed
[62] 336 NR NR 8.8 12.2 34.5 32.7 15.8 17.1 18.7 15.45 NR NR 0.25 1.63 75% ascites
Timolol
[63] 1 NR NR NR 24.9 23.6 8.4 10.0 16.5 14.4 NR NR -0.15 1.05 100% varices
Carvedilol
[60] 1848 7.5 6.4 1.39 1.28 4.6 5.5 26.4 23.5 7.3 8.2 19.0 15.2 13.7 11.9 1.0 1.9 Varices, PHVPG>1 2
Clonidine
[64] 168 6.41 5.40 1.05 1.33 5.2 3.4 30.4 27.4 10.2 9.7 20.1 17.6 19.1 13.2 1.75 1.25 100% Ascites
[65] 3/4 6.40 5.36 0.96 1.22 NR 31.3 28 11.0 11.4 20.3 16.6 21.1 13.6 1.45 1.85 100% Ascites
[66] 448 7.8 6.7 1.2 1.1 2.6 4.2 23.9 24.6 5.1 8.7 18.8 15.9 15.7 14.4 -2.15 1.45 40% ascites
Nitroglycerin
[67] ≈1/10 NR NR NR 22.5 18.9 4.6 3.6 17.9 15.1 NR NR 2.3 1/4 Sublingual
[68] 1 NR 0.93 0.919 NR 26.0 22.1 8.4 8.6 17.6 13.6 NR NR 1.85 2 Transdermal
[69] 1/3 7.42 6.75 1.34 1.1 6.1 4.0 29.2 29.3 8.3 8.2 20.9 21.1 15.7 14.4 0 00.1 Low dose IV, 53%
ascites
Vasopressin
[70] 1/2 NR NR NR 28.6 24.0 5.7 6.3 22.9 17.7 NR NR 2.0 2.6 Bleeding varices,
40% ascites
[71] 1/2 7.6 6.5 1.89 1.06 5.0 7.5 26.6 23.6 7.6 9.1 19.0 14.6 10.1 13.8 0.75 2.2 30 min IV inf
[72] 1/2 7.14 5.77 1.35 0.91 NR 17.8 12.7 6.7 7.3 11.1 5.4 8.22 5.93 2.25 2.85 40% ascites, IV inf
Terlipressin
[73] 1 NR NR NR NR 5.2 9 25.4 25.0 6.0 8.1 19.4 16.8 NR NR -0.85 1.3 Variceal gradient
reduction
Captopril
[74] 504 NR NR NR 22.9 20.7 15.0 12.1 7.58 9.32 NR NR 2.55 -0.5 100% ascites
[61] 2160 NR NR NR 24.8 21.1 9.3 7.1 15.6 13.0 NR NR 2.95 1.3 100% variceal bleed
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occurs with appreciable ascites), PHV =P A ≈ PFree (eq.
(13)) and (PL -P A) is described by:
PL − PA =( PPV + PHV)/2 − PA =( PPV + PA)/2 − PA
≈ (PWedge − PFree)/2 = PHVPG/2
(15)
It is only for this latter case that (PL -P A) is directly
determined by PHVPG. In the absence of gross ascites,
determination of (PL -P A)r e q u i r e sa ne s t i m a t eo f
ascites pressure (which usually is neglected in most stu-
dies of portal hemodynamics). Recognition of the impor-
tance of the two pressure domains and correctly
calculating (PL -P A) is crucial since, as will be shown,
minor differences (several mm Hg) in pressure may
determine the presence or absence of ascites. The dis-
cussion of the action of b-blockers (Section IIF) provides
an illustration of the importance of the difference
between calculations based on eq. 14 versus eq. 15.
In subjects with normal livers, PWedge and PFree are
about 6 and 4 mm Hg, respectively [80-82]. Since direct
measurement of PA in normal subjects with no overt
ascites is difficult, indirect approaches have been
employed [83]. Using the urinary bladder measurements,
Cobb et. al. [14] reported values of about 2 mm Hg for
PA in the normal supine subject. Substituting this value
into eq. (14), yields a (PL -P A)o fa b o u t3m mH gf o r
normal subjects. Estimates of the value of (PL -P A)i n
ascites subjects is uncertain because, as discussed above,
investigators have failed to distinguish between the two
pressure domains and direct measurements of PA are
not available. There is a weak correlation between
PHVPG and the presence or absence of ascites. In 3 stu-
dies of PHVPG in cirrhotic patients, the average values in
subjects without versus with ascites were 11.5 vs 16
[84]; 17.7 vs 19.1 [85] and 14.9 vs 17.8 mm Hg [86]. In
a prospective follow up of 122 cirrhotics undergoing a
TIPS procedure, Casado et. al. [87] reported that ascites
was a problem only in patients whose PHVPG remained
greater than 12 mm Hg. Substituting this value into eq.
(15), indicates that the value of PL -P A must be at least
6 mm Hg (twice the normal value) before appreciable
ascites is formed. This observation supports the assump-
tion in our model that there is a critical value of PL -P A
above which the liver capsule and/or lymphatics rupture,
allowing leakage of high protein tissue fluid into the
peritoneal space.
D. Intra-abdominal lymph drainage (Jlymph)
The volume of ascites reaches a steady-state when the
rate of leakage of protein from the liver equals the rate
of protein removal by lymph. Most of the peritoneal
cavity is drained via diaphragmatic lymphatics that
drain into the right lymph duct. These lymphatics have
complex stomatal openings on the peritoneal surface
that provide fixed drainage sites [19]. These drainage
sites are like holes in a balloon and, unlike the hepatic
vein or inferior vena cava, cannot be collapsed by high
intraperitoneal pressure. Since it is not possible to
directly measure this lymph flow, indirect methods
have been employed. The standard approach is to mea-
sure the kinetics of removal of labeled albumin from
peritoneal fluid. A major area of controversy in the
peritoneal dialysis literature is the interpretation of
these measurements since the rate of disappearance of
label from peritoneal fluid seemingly is about 10 times
greater than the rate of appearance of this label in
plasma [88,89] due to sequestration of the albumin in
tissue. The weight of evidence suggests that lymph
flow should be determined from the rate of appearance
of the peritoneal label in plasma. This rate (Jlymph)i s
Table 1 Hemodynamic responses to drugs in cirrhotic patients (Continued)
Enalaprilat
[75] 1/2 6.7 6.9 NR NR 32.1 25.6 11.2 10.8 21.0 16.1 NR NR 3.45 2.45 IV infusion
Losartan
[62] 336 NR NR 8.4 8.55 32.4 28.31 13.21 14.26 19.21 14.15 NR NR 1.53 2.53 63% ascites
[76] 5.8 5.7 NR NR 20.3 17.3 4.9 3.7 15.4 13.6 NR NR 2.1 0.9 Pre-ascitic, 4 week
Saralasin
[77] ≈1/2 6.5 5.97 1.42 1.35 4.8 4.3 28 24.0 10.8 10.2 17.2 13.78 12.1 10.2 2.31 1.71 100% ascites, IV inf
Somatostatin
[72] 1/2 6.59 6.38 3.7 1.1 0.89 4.1 19.5 16.2 7.2 7.6 12.3 8.6 3.32 7.82 1.45 1.85 40% ascites, IV inf
Fenoldopam
[78] 1 8.9 10.5 1.5 1.6 6.1 4.4 24.6 28.0 9.2 8.7 15.4 19.3 10.23 12.1 -1.45 -1.95 MAP: 84.6-61.8
decrease
Δt = time interval pre–post (hours), CO = cardiac output (liters/min), HBF = hepatic blood flow (liters/min), PRA = right atrial pressure (mm Hg),
Wedge = portal wedge pressure (mm Hg), Free = free portal pressure (mm Hg), PHVPG = Wedge - Free, Resistance = hepatic flow resistance = Gradient/HBF (mm
Hg/liter),
Δ(PL -P A) = change in pressure difference across the liver capsule–(pre - post), MAP = mean arterial pressure
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during peritoneal dialysis [90,91]. Henriksen et. al.
[92,93] have shown that in patients with cirrhotic
ascites, Jlymph is much greater, about 50-60 ml/hour.
The factors responsible for this increased lymph flow
are not well understood. These patients had greater
pressures (PFree of about 12 mm Hg) and ascitic
volumes (about 7 liters) than the dialysis patients
which may account for the difference. Zink and Green-
way [94] have shown in cats that peritoneal fluid and
protein absorption had an approximately linear depen-
dence on pressure.
It is well established that cirrhotic patients can be in a
steady state with roughly constant ascites volumes for
long time periods. This implies that as ascites volume
increases, there must be some compensating effect that
produces a balance between the rate of protein leak and
removal. As discussed above, a rise in PA should not
have a marked effect on the protein leak rate deter-
mined by (PL -P A) since this increase in PA produces
an equivalent increase in PL. Thus, the homeostatic
mechanism presumably is that an increase in PA
increases Jlymph as has been experimentally observed in
cats [94]. Quantitative support for this in humans is
provided by the measurements of Shear et. al. [95] of
the rate of formation of ascites following paracentesis. If
one assumes that the rate of lymph flow was 60 ml/
hour pre-paracentesis (see above) and 10 ml/hour post-
paracentesis (as observed in dialysis patients), the pre-
dicted net rate of ascites formation immediately after
paracentesis would be about 50 ml/hour (1.2 liters/day),
which is similar to what was observed by Shear et. al.
[95]. However, this is indirect evidence and, although
lymph flow must balance protein leak at steady state,
the exact rate of this flow in various situations needs
further study.
E. Protein concentration in ascitic fluid and the serum-
ascites albumin gradient (SAAG)
The model predicts that 1) hepatic lymph protein
should be approximately equal to plasma protein (eq.
(7)); 2) as the liver sinusoidal pressure is raised, a conco-
mitant rise in intestinal capillary pressure should wash
down the protein concentration in the intestinal tissue;
and 3) ascitic fluid protein should approximately equili-
brate with this washed down intestinal tissue protein
(eq. (8)) (which equals intestinal lymph protein). A cor-
ollary of predictions 2 and 3 is that as the severity of
portal hypertension increases, which causes an increas-
ing intestinal capillary pressure and decreasing intestinal
tissue protein, the ascitic fluid protein concentration
should also fall. Witte et. al. [13] measured the protein
concentration in ascites fluid and hepatic and intestinal
lymph in patients in varying stages of ascites. The mea-
sured lymph protein/plasma total protein ratios were:
control: hepatic = 0.88; intestinal = 0.7; early stage cir-
rhosis: hepatic = 0.8, intestine = 0.8, ascites = 0.65; late
stage: hepatic = 0.6; intestine = 0.12; ascites = 0.17.
These experimental observations are in qualitative
agreement with the above predictions. An important dif-
ferential diagnostic marker of ascites is the value of the
serum-ascites albumin gradient (SAAG). A SAAG of
≥1.1 gm% is strongly indicative of portal hypertension
(either cirrhotic or cardiac ascites) while all other causes
of ascites (e.g. infections, malignancy) tend to have
smaller gradients [96]. While the diagnostic accuracy of
the SAAG has been demonstrated empirically, the phy-
siology underlying this measurement has received little
attention. The values of the SAAG in various conditions
follow directly from the assumption in the model that
intestinal tissue and ascites fluid have similar albumin
concentrations (eq. (8)). In subjects with normal portal
pressure these concentrations are high, about 70% of the
plasma value, resulting in a low SAAG. In contrast, the
increase in intestinal capillary hydrostatic pressure and
the accompanying wash down of intestinal interstitial
protein produced by portal hypertension of any etiology
results in low ascites protein concentrations, hence a
high SAAG.
Although the above discussion is focused primarily on
cirrhotic ascites, cardiac ascites is also associated with a
SAAG of ≥1.1 gm%. In a series of patients with chronic
hepatopathy (68% with ascites), the average value of the
free hepatic vein pressure was 17 mm Hg, with a PHVPG
of 2 mm Hg [97]. Thus, the liver sinusoidal pressure is
about 18 mm Hg which, presumably, results in rupture
of liver lymphatics and leakage of protein into the peri-
toneal space. The corresponding intestinal capillary
pressure is about 22 mm Hg (3 mm Hg greater than
portal vein pressure) which should wash down intestinal
tissue albumin to a low value. Osmotic equilibration of
the ascitic albumin with this intestinal tissue results in a
large SAAG.
F. Medical treatment of ascites
Given the widespread use of diuretics to treat ascites, it
is surprising that the mechanism of benefit of these
drugs has received little attention. The challenge is relat-
ing the systemic effects of diuretics (alterations in blood
pressure, blood volume, systemic resistance and capaci-
tance, etc.) to the two local primary factors that deter-
mine ascites volume in the above model: 1) protein leak
from the liver surface as a result of increased (PL -P A)
and 2) intra-abdominal lymph drainage. In this section
we will compare the hemodynamic actions of diuretics
that alleviate ascites, with the actions of a number of
other drugs that have been evaluated for potential utility
in the treatment of portal hypertension
Table 1 summarizes the reported hemodynamic
changes produced by 15 different drugs in cirrhotic
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Page 8 of 18subjects. As discussed above (Section IIC), there are two
different relationships for (PL -P A), depending on
whether there is no ascites and the intra-abdominal
pressure (PA) is assumed to be small (eq. (14)) or there
is appreciable ascites with an increased PA (eq. (15)).
The penultimate column in Table 1 lists the calculated
drug-induced changes in (PL -P A) for both of these
cases using the following equations:
 (PL − PA)= ( P
pre
HepWedge + P
pre
HepFree − P
post
HepWedge − P
post
HepFree)/2 Noascites (16)
 (PL − PA)= ( P
pre
HPVG − P
post
HPVG)/2 Ascites (17)
where it is assumed for eq. (16) that the drug does not
change the intra-abdominal pressure. For most of the
studies listed in Table 1 there was either no or mild
ascites, and eq. (16) should be used. Also listed in Table
1 is the change in the hepatic blood flow (FL), the gradi-
ent (PHVPG), the corresponding liver resistance (RL =
PHVPG/FL) and the right atrial pressure (PRA).
The administration of the spironolactone or furose-
mide decreased PHVPG by about 20% [51-55] (Table 1).
This decrease primarily resulted from a decrease in the
wedge pressure whereas there was only a small change
in free hepatic pressure. This decrease in PHVPG was
roughly proportional to the decreased hepatic blood
flow; hence there was little change in hepatic resistance.
It is also notable that, in the two studies where right
atrial pressure was measured, the diuretics produced
about a 2 mm Hg fall in pressure. In summary, the
alterations in local peritoneal fluid balance induced by
diuretic therapy presumably are the result of two major
systemic changes: 1) a decrease in cardiac output with a
corresponding fall in hepatic blood flow and PHVPG, and
2) a decrease in right atrial pressure.
Administration of non-selective beta blockers (propra-
nolol, timolol, carvediol), cause reductions in PHVPG
comparable to that observed with diuretics (Table 1).
However, beta blockers are not considered useful for the
treatment of ascites, and Rector and Reynolds [98] have
shown that the addition of propranolol to diuretic ther-
apy reduces renal sodium excretion and may interfere
with the action of diuretics. On the other hand, beta-
blockers consistently have been demonstrated to reduce
the incidence of bleeding from esophageal varices
whereas no such benefit has been noted with diuretics.
Surprisingly, there has been little discussion of this para-
doxical difference in efficacy of diuretics versus beta-
blockers in the treatment of complications of portal
hypertension, given that both classes of drugs seemingly
produce similar reductions in portal hemodynamics as
measured by the PHVPG. An important difference
between the action of these drugs is that in marked con-
trast to diuretics, about 50% of the decrease in PHVPG
induced with beta blockers results from an increase in
the free hepatic pressure (Table 1). Thus the estimated
decrease in (PL -P A) using eq. (16) is less than half that
observed with diuretics. Again, the local changes can be
directly associated with the systemic effects, with the
decrease in the gradient explained by the decrease in
cardiac output and hepatic blood flow (with negligible
change in resistance) and the increase in the free portal
pressure explained by the increased right atrial pressure.
These data demonstrate why PHVPG is not directly cor-
related with (PL -P A) in patients without gross ascites.
For example, a drug that increased the free hepatic pres-
sure but had no effect on the wedge pressure would
decrease PHVPG but would actually increase (PL -P A)
according to eq. (16). It has been shown that the devel-
opment of varices or variceal hemorrhage is strongly
correlated with both the absolute value of PHVPG [99]
and the response of PHVPG to beta blockers [48]. For
varices, the important parameter is the difference
between the portal vein pressure and the pressure in the
shunted systemic vein. One would expect that PHVPG
should be a good approximation of this pressure differ-
ence. Thus, PHVPG may influence the tendency to bleed-
ing from varices, even though this pressure gradient
does not directly correlate with (PL -P A), which is the
crucial parameter for the development of ascites.
Clonidine, an a2 receptor agonist, is unique among
the 15 drugs in Table 1 in that its major action seems
to be a decrease in hepatic resistance which produces a
corresponding decrease in PHVPG with little change in
hepatic blood flow [64-66]. In clinical trials of clonidine
for the treatment of ascites, clonidine by itself was not
effective but the combination of clonidine and spirono-
lactone produced a greater weight loss and ascites
decrease than spironolactone alone [100]. Because cloni-
dine does not decrease portal blood flow, it is not
regarded as an effective treatment for gastroesophageal
varices [101,102]
Also listed in Table 1 are the portal hemodynamic
responses to nine other drugs. The activation of the
renin-angiotensin-aldosterone (RAAS) system has a cen-
tral role in the standard “forward theory” of ascites for-
mation [6]. The RAAS antagonists in Table 1 (captopril,
enalapril, losartin, saralasin) reduce PHVPG with little or
no change in PFree. A recent systematic meta-analysis of
the RAAS antagonists concluded that the PHVPG
response was a function of the Child Pugh class [103].
Despite this decrease in PHVPG, ACE inhibitors do not
seem to be of benefit in the treatment of ascites [104].
Although vasopressin and terlipressin (vasopressin ago-
nist) decreased PHVPG, this decrease resulted primarily
from an increase in PRA and PFree (Table 1) and, there-
fore, they are unlikely to be beneficial in the treatment
of ascites. The most recent candidate drug classes for
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Page 9 of 18the treatment of ascites are the vasopressin V2 receptor
antagonists (vaptans). These drugs increase plasma
sodium by increasing solute free water excretion and it
was hoped they would be useful in ascites. Although
short term trials of satavaptan suggested a positive
effect, a recent long term randomized trial concluded
that it is not beneficial in the treatment of ascites [105].
It is clear from the results in Table 1 that one cannot
explain the therapeutic action of diuretics based only on
the reduction of PHVPG s i n c em a n yo t h e rd r u g st h a t
apparently are not effective in the treatment of ascites
have similar actions on PHVPG.
Serum albumin concentration commonly is decreased
in cirrhosis. The resultant fall in plasma oncotic pres-
sure is only partially offset by the increased in serum
globulins observed in cirrhosis. The use of albumin infu-
sion for the treatment of ascites is controversial. In a
comprehensive review of this literature, Trotter et. al.
[106] concluded that, although short term therapy (11
to 16 days) was not useful, there was suggestive evi-
dence that long duration albumin infusion (27 days to 2
years) in association with diuretics was beneficial in
terms of ascites resolution and ascites redevelopment. In
the only controlled trial of albumin in the treatment of
ascites, Gentilini et. al. [107] found that addition of
albumin to diuretic therapy resulted in a statistically sig-
nificant increase in the number of responders and sig-
nificantly reduced the redevelopment of ascites. The
interpretation of these results is complicated because
albumin also has systemic renal and cardiovascular
effects. For example, albumin infusions may increase
blood volume and central venous pressure which would
increase (PL -P A) and exacerbate the ascites. The effects
of albumin predicted by our model are small because
any change in the amount of protein leaking from the
liver will be roughly balanced by the change in the
intestinal tissue protein. The model predicts that albu-
min would affect ascites formation at very high portal
pressures because, as was discussed in Section IIA (see
eq. (9)), there is a limit to the intestinal capillary pres-
sure at which Starling force balance can be achieved
and this limit is set by the plasma colloid osmotic pres-
sure. Thus, in severe portal hypertension that produces
intestinal capillary pressures that approach or exceed
plasma oncotic pressure, there should be an increase in
t h er a t eo fa s c i t e sf o r m a t i o n with decreasing albumin.
The quantitative model discussed in Section III provides
predictions of the influence of plasma oncotic pressure
on ascites volume over the entire range of portal
pressures.
If one assumes that the model presented in this review
is correct, then diuretics must act through the two local
factors (PL -P A)a n dJ lymph. Diuretics decrease (PL -P A)
from 1 to 2 mm Hg, which represents about a 10-20%
decrease from the initial value. Another action of diure-
tics which stands out from all the other drugs listed in
Table 1 is the relatively large decrease in right atrial
pressure (PRA). This lowering of PRA by spironolactone
or furosemide is apparently not dependent on the diure-
tic action since decreases of 2-5 mm Hg have been
observed in chronic renal failure patients on hemodialy-
sis [108,109]. This decrease in PRA, which has not been
previous emphasized, has two separate effects on ascites.
First, for low peritoneal pressures (eq. (12)), PL is addi-
tive to PRA and a decrease in PRA directly reduces (PL -
PA) and the liver leak rate. Second, as discussed in more
detail in the description of the quantitative model (Sec-
tion III), this decrease in PRA may increase the rate of
peritoneal fluid drainage (Jlymph). Although the effect of
diuretics on protein leak and Jlymph are relatively small,
if, pre-diuretic, the rate of leak and lymph flow are
equal and opposite, these small changes can shift the
balance and lead to a reduced ascitic volume. In the
next section a quantitative model is developed that
demonstrates that, under some conditions, these small
changes (20% reduction in PHVPG and 3 mm Hg reduc-
tion in PRA) surprisingly can lead to the complete reab-
sorption of ascites. We believe that this is the first
attempt to provide a mechanistic explanation for the
efficacy of diuretics.
III. Quantitative physical modeling
This section will present a quantitative model of ascites
formation and removal and the influence of various phy-
siological perturbations on the model’sp r e d i c t i o n s .T h e
first part of this analysis assumes that the system is in a
steady state with a constant ascites volume. For this
case JI (eq. (4)) equals JC (eq. (1)) and (assuming PI =
PA) one can express the fluid flux from the blood to the
intraperitoneal space as:
JI = LT[(PC − PA) − ( P −  A)]
LT = LILC/(LI + LC)
(18)
where LT is the total blood to peritoneal space
hydraulic conductance of the intestine (i.e., the series
conductance of the capillary and mesenteric mem-
branes). The model further assumes that the intact liver
capsule is impermeable to protein, and fluid flux from
the liver into the peritoneal cavity occurs only when a
critical pressure difference (= PBreak) between liver tissue
(PL) and peritoneal space (PA)i sr e a c h e dt h a tr e s u l t si n
rupture of the liver lymphatics and/or capsule. Above
this break pressure, the rate of flux of fluid from the
liver lymphatics into the peritoneal cavity is a function
o ft h ed i f f e r e n c eb e t w e e nt h e liver tissue and intraperi-
toneal pressure (for pressure differences greater than
PBreak). Thus:
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=0 PL − PA <= PBreak
(19)
where LL is the conductance of the ruptured
lymphatics.
The model assumes that lymph flow from the perito-
neal cavity is proportional to the difference between the
intraperitoneal (PA) and right atrial pressures (PRA):
JLymph = LY(PA − PRA + Pmin) PA > PRA − Pmin
=0 PA < PRA − Pmin
(20)
where Pmin determines the zero flow rate and will be
assumed equal to 2 mm Hg. The steady state ascites
volume requires that the intra-abdominal lymph flow
equals the sum of the intestinal plus liver fluxes:
Jlymph = JI + JL (21)
Also, the total protein leak from the liver must equal
the amount removed by the lymph:
m P JL =  A Jlymph (22)
where m is the concentration of protein in the liver
exudate as a fraction of the plasma protein (ΠP). It will
be assumed that the intestinal capillary pressure (PC)i s
3 mm Hg greater than the portal vein pressure (PP) and
that the hepatic vein pressure (PHV)i se i t h e ra )2m m
greater than the right atrial pressure (PRA)i nt h e
absence of gross ascites; or b) equal PA if PA is greater
than (PRA +2):
PC = PRA + PHPVG +5 PA < PRA +2
= PA + PHPVG +3 PA > PRA +2 (23)
where the gradient PHVPG i st h ep r e s s u r ed r o pa c r o s s
the liver (= PPV -P HV). Finally, it will be assumed that
the ascites volume is proportional to the ascites pres-
sure:
Volume = Vmin + D ∗ [PA − Pmin] (24)
where Vmin is the ascites volume found normally (100
ml) when PA =P min = 2 mm Hg and D is the peritoneal
compliance. Equations (18)-(24) provide a complete
steady state description of the system.
Estimates of the values of the above parameters can be
obtained by using the following values for a “typical”
ascites patient: PHVPG = 20 mm Hg, ascitic hydrostatic
pressure (PA) = 10 mm Hg [47], ascites osmotic pres-
sure (ΠA) = 30% of plasma [47,96], an elevated PRA =5
mm Hg (Table 1) and Jlymph = 55 ml/hour [92,93]. It
will be assumed that PBreak = 8 mm Hg and that the
liver exudate has a protein concentration equal to 0.8 (=
m) of the plasma, similar to the value found for liver
lymph [13]. In the following, the equivalent colloid
osmotic pressure (Π)w i l lb eu s e df o rt h ep r o t e i nc o n -
centration, assuming a plasma value (Πp)=2 5m mH g .
Using Jlymph = 55 ml/hour in eq. (20), LY =7 . 8 6m l /
hour/mm Hg (assuming PRA = 5 and Pmin = 2). Diluting
the liver exudate protein from a plasma fraction of 0.8
(= m) to the ascites value of 0.3 requires JL = 0.375JY =
20.6 ml/hour and JI = 0.625JY = 34.4 ml/hour. Using the
assumed “typical” ascitic pressures (PHV = 10, PP = 30,
PL = 20 and PL -P A = 10 mm Hg), the net driving force
above PBreak is 2 mm Hg, corresponding to an LL = 10.3
ml/hour/mm Hg (eq. (19)). Using these pressures and a
ΠP of 25 mm Hg in eq. (18), the value of the “intestinal”
ultrafiltration coefficient = LT = 6.25 ml/hour/mm Hg.
The peritoneal dialysis literature [110] uses a value for
LT of 4.5 ml/hour/mm Hg for a 2 liter exchange
volume. The exchange surface would be larger for the 5
to 10 liter ascitic volumes that are common in ascites
patients. Thus, a somewhat higher LT (6.25 ml/hour/
mmHg) was employed in the model. Finally, a compli-
ance of the peritoneal cavity (D) of 0.8 liters/mm Hg
will be used, based on experimental measurements in
humans of the changes in peritoneal pressure following
paracentesis [111,112].
Figure 2 shows the steady state peritoneal volume
(top), protein concentration (middle) and lymph flow as
the PHVPG varies from 6 mm Hg (the pressure when
l i v e re x u d a t i o ns t a r t s )t o2 5m mH g .A tag r a d i e n to f
18.15 mm Hg, there is shift between the low pressure
domain where PHV =P RA + 2, and the high ascitic pres-
sure domain where PHV =P A (eq. (23)). The ascites pro-
tein concentration is expressed in terms of its equivalent
colloid osmotic pressure. (For a normal subject with
PHVPG =2 ,P A =2 ,P RA =2 ,P HV = 4, the osmotic activ-
ity of the steady state ascites protein concentration
s h o u l db ea b o u t2 0m mH g . )T h ea s c i t e sp r o t e i ns t a y s
in a rather narrow range, falling from about 11 mm Hg
when the ascites fluid begins to form, to a minimum of
about 7 mm Hg at PHVPG of 18 mm Hg and then slowly
rising to about 8 mm Hg. Assuming an albumin/total
protein fraction of 0.65, these values correspond to albu-
min concentrations of about 2.5, 1.75 and 1.95 gm%
respectively [113]. For the assumed plasma colloid
osmotic pressure of 25 mm Hg (albumin concentration
of 4.45 gm%), these values correspond to a SAAG of
1.95, 2.75 and 2.5 gm%. The fall in ascites protein
results from the wash down of intestinal tissue protein
as the capillary blood pressure increases. At high PHVPG
the leak of high protein fluid from the liver makes a
relatively greater contribution to the total ascitic fluid
formation, producing the increase in the ascitic protein
concentration.
It is of interest to see how the ascites volume is
altered by the hemodynamic changes produced by
diuretics. As indicated in Table 1, diuretics reduce both
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right atrial pressure (PRA). Figure 3 shows how the
steady state ascites volume in the original untreated
condition (black line) is altered by either a) a 20%
decrease in gradient (green line); b) a reduction in PRA
from 5 to 2 mm Hg (blue line), or c) a combination of
both (a) and (b) (red line) as a function of the initial
PHVPG. For an initial gradient of 20 mm Hg, the ascites
volume is reduced from about 6.5 to 1.0 liter if diuretics
induced both of the above noted changes in PHVPG and
PRA. If the initial gradient is 16 mm Hg or less, diuretics
should produce complete reabsorption of the ascites.
The reductions in PHVPG and PRA both contribute to
the ascites reabsorption, but in different ways. At high
initial PHVPG (> 18 mm Hg), when the hepatic vein pres-
sure becomes decoupled from PRA (eq. (13)), lowering
PRA (Figure 3, blue line) has a relatively small effect,
while lowering PHVPG (green line) has a larger effect. In
contrast, in the low pressure regime when the hepatic
vein pressure is equal to (PRA +2 )( e q .( 1 2 ) )l o w e r i n g
PRA (blue line) has a dramatic effect. For example, if the
initial PHVPG is less than 13 mm Hg, lowering PRA from
5 to 2 mm Hg is enough by itself to completely resolve
the ascites. These predicted results indicate that the
small changes in PHVPG and PRA clinically achievable
with diuretics (see Table 1) can link the systemic
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 The model prediction for the steady state ascites
volume (top), colloid osmotic pressure (middle) and lymph
flow (bottom) as a function of the hepatic vein pressure
gradient (PHVPG = wedge - free).
Figure 3 Decrease in the ascites volume from the untreated
case (black line) produced by a) decrease in PHVPG by 20%
(green), b) decrease of right atrial pressure (PRA) from 5 to 2
mm Hg (blue) and c) decrease in both PHVPG by 20% decrease
and PRA from 5 to 2 mm Hg (red) as a function of the original
PHVPG before treatment.
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Page 12 of 18changes induced by diuretics to fluid accumulation in
the abdomen.
As discussed in Section IIF, propranolol produces a
decrease in the PHVPG similar to that of the diuretics,
but it also produces an increase in PFree that results
from an increase in PRA. Figure 4 shows the predicted
change in ascites volume (red line) produced by a 20%
decrease in PHVPG and an increase in PRA from 5 to 7
mm Hg, similar to what is seen for propranolol (Table
1). It can be seen that for initial PHVPG less than about
18 mm Hg, propranolol would be predicted to produce
an increase in ascites volume, despite the decrease in
PHVPG.
A standard treatment for cirrhotic ascites is surgically
produced portal systemic shunting [114]. Assuming that
this procedure reduces portal flow with no change in
liver resistance or central venous pressure, then the per-
cent reduction in PHVPG is equal to the percent reduc-
tion in liver blood flow. Figure 5 shows the reduction in
ascites volume produced by a 20%, 35% and 50% reduc-
tion in PHVPG or, equivalently, liver flow as a function of
the initial PHVPG. It can be seen that in order to reduce
ascites by shunting, large reductions (about 50%) in flow
are required. This is consistent with the results of Rogri-
guez-Laiz et. al. [115] that showed that transjugular
intrahepatic portasystemic shunts (TIPS) reduced liver
blood flow by about 50%.
An important prediction of the model is that central
venous pressure (PRA) plays a major role in ascites
volume, independent of the PHVPG. For example, in a
patient with an initial PHVPG of 16 mm Hg, a diuretic
induced reduction in PRA of just 3 mm Hg would reduce
ascites volume from 3.5 liters to a clinically undetectable
0.8 liters, with no change in PHVPG. Thus, the model is
consistent with the clinical observation that that there
m a yb eo n l yal o o s ec o r r e l a t i o nb e t w e e nt h es e v e r i t yo f
ascites and PHVPG.I ts h o u l da l s ob ep o i n t e do u tt h a t
there need be no relationship between the initial PHVPG
of subjects and their responsiveness to diuretics. For
example a patient with an initial PHVPG of 16 mm Hg
who cannot increase renal sodium output with diuretics
(i.e., cannot reduce PRA or PHVPG in response to diure-
tics) will maintain an ascitic volume of about 3.5 liters. In
contrast, a subject with an initial PHVPG of 20 mmHg
w h oi sr e s p o n s i v et od i u r e t i c s ,s u c ht h a tt h eP RA falls by
3 mmHg and the gradient by 4 mmHg, will have a reduc-
tion in ascitic volume from 6.5 liters to only 1 liter.
As discussed in Section IIF, it is expected that changes
in plasma albumin should have a complicated effect on
the severity of ascites. Figure 6 plots the predicted
ascites volume as a function of PHVPG for plasma colloid
o s m o t i cp r e s s u r eo f2 5m mH g( b l a c kl i n e ) ,2 0m mH g
(red), 15 mm Hg (green) and 10 mm Hg (blue). As
expected (Section IIF), the increase in ascites volume
produced by decreasing albumin is greatest at higher
portal pressures and becomes negligible at PHVPG less
than about 14 mm Hg. Even at PHVPG above14 mm Hg,
the effect of decreasing oncotic pressure is relatively
minor until this pressure reaches a value of 10 mm Hg
(equivalent to a serum albumin of about 1.5 gm%).
Thus, it is not surprising that many investigators have
concluded that serum albumin infusion is not efficacious
for the reduction of ascites. It also is apparent that no
Figure 4 Change in the ascites volume from the untreated
case (black line) produced by a decrease in PHVPGby 20% and
an increase in PRAfrom 5 to 7 mm Hg (red) as a function of the
original PHVPGbefore treatment.
Figure 5 Change in the ascites volume from the untreated
case (black line) produced by reduction of either PHVPGor,
equivalently, liver blood flow by 20% (red), 35% (green) or
50% (blue) as a function of the original PHVPGbefore treatment.
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Page 13 of 18ascites would be expected with very low serum albumin
concentrations, providing the PHVPG is normal (< 6 mm
Hg). This prediction is borne out by the absence of
ascites in subjects with congenital hypoalbumenemia
[116,117].
A time dependent model using the above relations and
parameters was also developed. This is a detailed, general
model which also includes the “intestinal” lymph flow
a n dt i s s u ec o m p l i a n c e .T h et o t a l“intestinal” hydraulic
conductance (LT, eq. (18)) was divided equally between
the intestinal capillaries and the intestinal mesothelium.
(The following results do not depend significantly on this
assumption). The solution requires the solution of 4
simultaneous differential equations. The details are
described in the Additional file 1 Section II. Figure 7
shows the time dependent ascites volume change when,
at time = 0, the gradient (PHVPG) is suddenly raised to 20
mm Hg and the right atrial pressure (PRA) is increased to
5 mm Hg. After 30 days, when the system has reached a
steady state with a volume of 6.5 liters, the gradient is
suddenly reduced by 20% (to 16 mm Hg) and PRA is
reduced to 2 mm Hg. Over a period of about 5 days, the
ascitic volume is reduced to about 1 liter. Figure 8 shows
a similar plot, with the gradient raised to 16 mm Hg. A
20% reduction in gradient (and PRA reduced from 5 to 2)
at 30 days leads to complete reabsorption of the ascites
over a period of about 5 days. Figure 9 shows a plot of
the volume change that might be expected following
paracentesis. At t = 0 the gradient was raised to 20 mm
Hg (PRA = 5) and the system reached a steady state at 30
days. Then, over a 12 hour period, 5.3 liters of ascitic
fluid was removed following which the volume returned
back to its initial volume over a period of about 5 days.
The time dependence of these volume changes is similar
to what is observed clinically [95].
We are unaware of any other attempts to quantitatively
model ascites. The present model, which seemingly takes
into account all factors involved in ascites accumulation,
provides predictions that are in good accordance with
Figure 6 Ascites volume as a function of PHVPGfor a plasma
colloid osmotic pressure of 25 mm Hg (black line), 20 mm Hg
(red), 15 mm Hg (green), and 10 mm Hg (blue).
PHVPG = 20 mm Hg 
PRA = 5 mm Hg 
PHVPG = 16 mm Hg 
PRA = 2 mm Hg 
Figure 7 Time dependent change in ascites volume.A tt i m e0 ,
the PHVPG is raised to 20 mm Hg and PRA is raised to 5 mm Hg.
After a steady state is reached at 30 days, PHVPG is reduced by 20%
to 16 mm Hg and PRA is lowered to 2 mm Hg.
Gradient = 16 
PRA = 5 
Gradient = 12.8 
PRA = 2 
Figure 8 Time dependent change in ascites volume.A tt i m e0 ,
the PHVPG is raised to 16 mm Hg and PRA is raised to 5 mm Hg.
After a steady state is reached at 30 days, PHVPG is reduced by 20%
to 12.8 mm Hg and PRA is lowered to 2 mm Hg.
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Page 14 of 18the major clinical observations in ascites. However, it
should be emphasized that the model employs assump-
tions that have only indirect experimental support. Two
major assumptions are the quantitative linear pressure
dependence of both the fluid leak from the liver (eq. (19))
and the peritoneal lymph flow (eq. (20)). Although the
leak should be a function of (PL -P A), there is no evi-
dence for the simple linear relation that is assumed. We
are not aware of any measurements in humans that relate
to the pressure dependence of the drainage of the perito-
neal space. However, Zink and Greenway [94] showed in
cats that the peritoneal fluid and protein absorption had
an approximately linear dependence on pressure.
Another important assumption in eq. (20) is that the
lymph flow is sensitive to the central venous pressure
(PRA). Although there are a number of observations that
suggest that lymph flow is sensitive to thoracic duct pres-
sure [28,118-121] and systemic venous pressure
[122,123], these results are indirect and not conclusive.
Summary
As discussed in the Introduction, in recent years ascites
research largely has focused on the systemic changes
observed in cirrhosis with particular emphasis on the
“hyperdynamic circulation” syndrome. Although there is
an implicit assumption that these changes cause ascites,
there has been little discussion of the physiological link
between these systemic alterations and ascites formation.
We theorize that ascites formation is dependent on
just three factors: 1) the rate of protein leak from the
liver, which is a function of the difference between the
liver tissue pressure and the peritoneal pressure (PL -
PA); 2) the colloid osmotic fluid movement between the
intestinal tissue and the peritoneal space; and 3) the rate
of lymph drainage of the peritoneal space, which is a
function of the peritoneal pressure (PA) and the central
venous pressure (PRA). This theory is not entirely novel
in that other investigators [36,37,94,111] have recog-
nized the role of these factors in ascites. Of particular
importance is the work of Henriksen and colleagues
that provides measurements of these factors in humans
[33,47,92,93,111].
In the standard “Forward theory” of ascites formation,
there is a cycle of pathological events, ending with
sodium and water retention and plasma volume expan-
sion which then produce the ascites [6]. The mechanism
involved in this last step is either not discussed or
assumed to be an obvious result of the volume expan-
sion. In terms of the model we have presented, this
volume expansion must act through an increase in cen-
tral venous pressure (PRA) and/or an increase in liver
tissue pressure (PL) produced by an increase in liver
blood flow (as a result of increasing cardiac output).
The novel aspect of the present report is the develop-
ment of a quantitative model of ascites accumulation
based solely on physiologically relevant estimations of
(PL -P A) and lymphatic drainage of the peritoneal cav-
ity. The predictions of this model provide insight into a
number of poorly understood clinical observations of
the behavior of ascites in cirrhotic patients. For example,
the model provides a quantitative explanation for the
beneficial action of diuretics on ascites formation and
the lack of efficacy of beta blockers despite their ability
to reduce PHVPG. The model rather accurately predicts
the known magnitude and time course of the action of
diuretics on ascites. Lastly, the model provides a physio-
logical explanation for the use of measurements of the
SAAG to diagnose the existence of portal hypertension.
Notation
ΠP, ΠA, ΠL, ΠI, colloid osmotic pressure in plasma, peri-
toneal fluid, and interstitial fluid of liver and intestine.;
PC,P A,P S,P L,P I,P PV,P HV,P RA,P Wedge,P Free,P HVPG,
hydrostatic pressure in intestinal capillary, peritoneal
fluid, liver sinusoid, liver tissue, intestinal tissue, portal
vein, hepatic vein, right atrium, the hepatic wedge and
free pressures, and the hepatic vein pressure gradient (=
wedge - free).; JC,J I,J L,J lymph, fluid flow rate across
intestinal capillaries, intestinal mesothelium, liver cap-
sule and peritoneal lymph flow.; LC,L I,L T,h y d r a u l i c
conductivity across intestinal capillary, intestinal
mesothelium and total.; FL,R L, liver blood flow and
Paracentesis 
Figure 9 Time dependent change in ascites volume.A tt i m e0 ,
the PHVPG is raised to 20 mm Hg and PRA is raised to 5 mm Hg.
After a steady state is reached at 30 days, 5.3 liters of ascites fluid is
removed over a period of 12 hours and, over the next 10 days, the
ascites reforms.
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Page 15 of 18resistance.; Ly, peritoneal lymph flow conductance.; Pmin,
zero lymph flow pressure.; Vmin, peritoneal fluid volume
when PA =P min;P Break, pressure at which liver capsule
and/or lymphatics rupture.; m, protein concentration in
fluid leaking from liver as fraction of plasma protein.
Additional material
Additional file 1: Experimental support for model and details of
time dependent model solution.Experimental support for model and
derivation of time dependent model solution.
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